Guidance is provided by a board whose directors are executives from some of the most successful bioscience, pharmaceutical, and investment companies in America.
Jim Barrett, PhD, joined NEA, an investment company, in 2001 as a general partner. He specializes in biotechnology and works with members of NEA’s healthcare investment group on medical devices, healthcare information systems and healthcare services companies. Mr. Barrett’s present board memberships include Cardioxyl Pharmaceuticals, GlycoMimetics, Inc., Inhibitex, Inc. (INHX), Nucleonics, Inc., Peptimmune, Inc., Predictive Biosciences, Proteostasis Therapeutics, Inc., Psyadon Pharmaceuticals, Ruxton Pharmaceuticals, Sensors for Medicine and Science, Inc., Supernus Pharmaceuticals, Inc., Targacept, Inc. (TRGT), and Zosano Pharma, Inc. Mr. Barrett formerly served on the boards of CoGenesys (acquired by Teva Pharmaceutical Industries), lomai Corporation (acquired by Intercell A G), Medlmmune, Inc. (acquired by AstraZeneca) and Pharmion (acquired by Celgene). Prior to NEA, Mr. Barrett founded and served as chairman / CEO of Sensors for Medicine and Science (1997-2001), where he remains chairman. Prior to 1997, he led three NEA-funded companies, serving as chairman / CEO of Genetic Therapy, Inc. (1987-1995), president / CEO of Life Technologies (1985-1987), and president / CEO of Bethesda Research Labs (1982-1983). Prior to 1982, Mr. Barrett worked in various divisions of SmithKline. He holds a PhD in biochemistry from the University of Tennessee, an MBA from University of Santa Clara, and a BS in chemistry from Boston College. Josh Bilenker, MD, serves as a Partner of Aisling Capital. Previously, Dr. Bilenker was a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. Dr. Bilenker currently serves as a director of LensAR, Inc., T2 Biosystems and ViewRay, Inc and as a board observer at Aragon Pharmaceuticals. He is also a member of the Board of Directors at BioEnterprise in Cleveland, OH. Dr. Bilenker received his MD from The Johns Hopkins School of Medicine. He received his AB from Princeton, awarded summa cum laude in English.
Michael P. Doyle, PhD, is a Regent’s Professor of Food Microbiology and Director of the Center for Food Safety at the University of Georgia. He is an active researcher in the area of food safety and security and works closely with the food industry, government agencies, and consumer groups on issues related to the microbiological safety of foods. He serves on food safety committees of many scientific organizations and has served as a scientific advisor to many groups, including the World Health Organization, the Institute of Medicine, the National Academy of Science-National Research Council, the International Life Sciences Institute-North America, the Food and Drug Administration, the U.S. Department of Agriculture, the U.S. Department of Defense, and the U.S. Environmental Protection Agency. He is a Fellow of the American Academy of Microbiology, the International Association for Food Protection and the Institute of Food Technologists, and is a member of the Institute of Medicine of the National Academies. Jonathan T. Silverstein, JD, is a general partner of OrbiMed, a healthcare-focused investment company. Mr. Silverstein joined OrbiMed in 1998 to focus on private equity and structured transaction in small capitalization public biotechnology and medical device companies. Mr. Silverstein was previously a director of life sciences in the Investment Banking Department at Sumitomo Bank, and an associate at Hambro Resource Development. Mr. Silverstein holds a JD and MBA from the University of San Diego, and a BA in economics from Denison University. Currently, Mr. Silverstein is the chairman of two companies Enobia and Cerapedics, and a director of three companies, SuperDimension, Glaukos, and NxStage Medical (NXTM). He has been a director or observer in more than a dozen companies including: LifeCell (LIFC), Given Imaging (GIVN), Cerexa (sold to Forest Labs), Peninsula Pharmaceuticals (sold to JNJ), Predix (sold to EPIX), Avanir (AVNR), Orthovita (VITA), Auxillium (AUXL), Bioenvision (sold to Genzyme), Adiana (sold to Cytyc), and Adolor (ADLR). Paul G. Thomas joined Roka Bioscience as CEO and Founder in September 2009. Mr. Thomas previously served as Chairman, Chief Executive Officer and President of LifeCell Corporation, a publicaly traded regenerative medicine company, from 1998 until it was acquired by KCI in 2008. Prior to joining LifeCell, Mr. Thomas held various senior positions during his tenure of 15 years with Ohmeda, a world leader in inhalation anesthetics and acute care pharmaceuticals. Mr. Thomas received his M.B.A. degree from Columbia University Graduate School of Business and completed his postgraduate studies in Chemistry at the University of Georgia Graduate School of Arts and Science. He received his B.S. degree in Chemistry from St. Michael’s College in Vermont. Mr. Thomas serves as a Director of AbioMed, Inc. (NASDAQ: ABMD) a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Mr. Thomas also serves as a Director of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) focused on the commercialization of a life-altering therapy for debilitating and fatal orphan diseases. Michael Watts is vice president and general manager for diagnostics at Hologic Gen-Probe. In his current role, Mr. Watts oversees Hologic’s product franchises in transplant diagnostics, respiratory infectious diseases, prostate oncology, pharmaceutical services and agricultural biotechnology. He joined Gen-Probe in November of 2003 as senior director of investor relations and corporate communications, was promoted to vice president in 2009 after assuming responsibility for several other staff functions, and began managing the company’s acquired businesses in 2011. Before joining Gen-Probe, Mr. Watts was director of investor relations and corporate communications at Ligand, and director of strategy for Baxter BioScience. He also spent seven years at Merck in a variety of corporate communications, marketing support, public affairs and sales roles. He holds an MBA from the Anderson School at UCLA and a BS from the Medill School of Journalism at Northwestern University.